All publications

Export 13 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Prevalence  [Clear All Filters]
2014
UK HIV Drug Resistance Database.  2014.  The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.
2013
De Luca A., Dunn DT, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
2012
Castro H, Pillay D, Sabin CA, Dunn DT.  2012.  Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.
Dolling D, Phillips AN, Delpech V, Pillay D, Cane P A, Crook A.M, Shepherd J., Fearnhill E, Hill T, Dunn DT.  2012.  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.
Donegan K.L, Walker A.S, Dunn DT, Judd A, Pillay D, Menson E, Lyall H., Tudor-Williams G, Gibb DM.  2012.  The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A, Churchill D, Williams I, Geretti AM et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.
2010
Mackie N, Phillips AN, Kaye S, Booth C, Geretti AM.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S.  2010.  Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 24:2397-401.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B., Pillay D, Dunn DT.  2010.  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.
Bansi L, Geretti AM, Dunn DT, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips AN et al..  2010.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.
UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study(UK CHIC).  2010.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 50:1275-85.
2008
Dunn DT, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin CA, Phillips AN.  2008.  Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 13:771-7.
2005
Cane P A, Chrystie I, Dunn DT, Evans B., Geretti AM, Green H, Phillips AN, Pillay D, Porter K, Pozniak A et al..  2005.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.